Deutsche Bank’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-74,522
| Closed | -$1.31M | – | 4519 |
|
|
2021
Q3 | $1.31M | Buy |
74,522
+4,498
| +6% | +$52.6K | ﹤0.01% | 2440 |
|
|
2021
Q2 | $679K | Buy |
70,024
+64,203
| +1,103% | +$604K | ﹤0.01% | 3027 |
|
|
2021
Q1 | $63K | Buy |
5,821
+749
| +15% | +$9.26K | ﹤0.01% | 4182 |
|
|
2020
Q4 | $74K | Sell |
5,072
-132,589
| -96% | -$1.91M | ﹤0.01% | 3998 |
|
|
2020
Q3 | $1.96M | Buy |
137,661
+120,761
| +715% | +$1.2M | ﹤0.01% | 1757 |
|
|
2020
Q2 | $137K | Sell |
16,900
-2,463,676
| -99% | -$15.2M | ﹤0.01% | 3302 |
|
|
2020
Q1 | $10M | Buy |
+2,480,576
| New | +$9.38M | 0.01% | 912 |
|
|
2019
Q3 | – | Sell |
-8,500
| Closed | -$2K | – | 5429 |
|
|
2019
Q2 | $2K | Sell |
8,500
-3,800
| -31% | -$1.96K | ﹤0.01% | 5201 |
|
|
2019
Q1 | $8K | Buy |
+12,300
| New | +$15K | ﹤0.01% | 4975 |
|
|
2018
Q4 | – | Sell |
-85,057
| Closed | -$493K | – | 5540 |
|
|
2018
Q3 | $493K | Sell |
85,057
-37,000
| -30% | -$209K | ﹤0.01% | 3793 |
|
|
2018
Q2 | $732K | Buy |
122,057
+101,738
| +501% | +$649K | ﹤0.01% | 3626 |
|
|
2018
Q1 | $146K | Sell |
20,319
-94,969
| -82% | -$720K | ﹤0.01% | 4344 |
|
|
2017
Q4 | $835K | Buy |
115,288
+109,406
| +1,860% | +$906K | ﹤0.01% | 3316 |
|
|
2017
Q3 | $30K | Sell |
5,882
-3,218
| -35% | -$15.1K | ﹤0.01% | 4489 |
|
|
2017
Q2 | $40K | Buy |
9,100
+1,700
| +23% | +$9.4K | ﹤0.01% | 4428 |
|
|
2017
Q1 | $45K | Buy |
7,400
+1,300
| +21% | +$7.62K | ﹤0.01% | 4264 |
|
|
2016
Q4 | $34K | Buy |
6,100
+1,523
| +33% | +$15.2K | ﹤0.01% | 4459 |
|
|
2016
Q3 | $66K | Buy |
4,577
+1,977
| +76% | +$22.8K | ﹤0.01% | 4095 |
|
|
2016
Q2 | $22K | Sell |
2,600
-3,578
| -58% | -$37.2K | ﹤0.01% | 4725 |
|
|
2016
Q1 | $57K | Buy |
6,178
+904
| +17% | +$7.62K | ﹤0.01% | 4274 |
|
|
2015
Q4 | $66K | Buy |
+5,274
| New | +$73.3K | ﹤0.01% | 4263 |
|
|
2015
Q3 | – | Sell |
-7,600
| Closed | -$165K | – | 5416 |
|
|
2015
Q2 | $165K | Buy |
7,600
+1,200
| +19% | +$27.4K | ﹤0.01% | 3979 |
|
|
2015
Q1 | $129K | Buy |
+6,400
| New | +$94.4K | ﹤0.01% | 4016 |
|
Other funds holding TRIL
Deutsche Bank's TRIL Position: Q4 2021 in Review
Deutsche Bank sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 74,522 shares — an estimated $1.31M sold.
Deutsche Bank first reported a position in TRIL in Q1 2015 and held it in 23 quarters. The position peaked at $10M in Q1 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Deutsche Bank reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Deutsche Bank sold 74,522 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.31M.
- Deutsche Bank first reported a position in Trillium Therapeutics Inc. in Q1 2015 and held it in 23 quarters.
- Deutsche Bank's Trillium Therapeutics Inc. position peaked at $10M in Q1 2020.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Deutsche Bank's 13F filing for Q4 2021, filed 11 Feb 2022.